Log in

NYSE:HUM - Humana Stock Price, Forecast & News

$375.85
-4.35 (-1.14 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$370.80
Now: $375.85
$380.00
50-Day Range
$333.09
MA: $360.28
$380.20
52-Week Range
$225.65
Now: $375.85
$381.04
Volume837,733 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio18.72
Dividend YieldN/A
BetaN/A
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryManaged Health Care
SectorN/A
CUSIP44485910
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees41,600
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive HUM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.


Humana (NYSE:HUM) Frequently Asked Questions

What is Humana's stock symbol?

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

How often does Humana pay dividends? What is the dividend yield for Humana?

Humana announced a quarterly dividend on Thursday, October 24th. Investors of record on Tuesday, December 31st will be paid a dividend of $0.55 per share on Friday, January 31st. This represents a $2.20 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Monday, December 30th. View Humana's Dividend History.

How were Humana's earnings last quarter?

Humana Inc (NYSE:HUM) released its quarterly earnings results on Wednesday, February, 5th. The insurance provider reported $2.28 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.20 by $0.08. The insurance provider earned $16.30 billion during the quarter, compared to analysts' expectations of $16.15 billion. The company's revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.65 EPS. View Humana's Earnings History.

When is Humana's next earnings date?

Humana is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Humana.

What guidance has Humana issued on next quarter's earnings?

Humana updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of $18.25-18.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $18.63.

What price target have analysts set for HUM?

16 brokerages have issued 12 month price targets for Humana's stock. Their forecasts range from $290.00 to $460.00. On average, they anticipate Humana's share price to reach $380.50 in the next year. This suggests a possible upside of 1.2% from the stock's current price. View Analyst Price Targets for Humana.

What is the consensus analysts' recommendation for Humana?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.

Has Humana been receiving favorable news coverage?

News stories about HUM stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Humana earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the insurance provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Humana.

Are investors shorting Humana?

Humana saw a decrease in short interest in January. As of January 31st, there was short interest totalling 1,930,000 shares, a decrease of 11.5% from the January 15th total of 2,180,000 shares. Based on an average daily trading volume, of 934,800 shares, the days-to-cover ratio is currently 2.1 days. Approximately 1.5% of the shares of the stock are sold short. View Humana's Current Options Chain.

Who are some of Humana's key competitors?

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Alibaba Group (BABA), Mastercard (MA), Walt Disney (DIS), Visa (V), Boeing (BA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Cigna (CI).

Who are Humana's key executives?

Humana's management team includes the folowing people:
  • Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
  • Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)
  • Mr. Timothy S. Huval, Chief HR Officer (Age 53)
  • Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
  • Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51)

Who are Humana's major shareholders?

Humana's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (4.71%), State Street Corp (4.36%), Renaissance Technologies LLC (2.23%), Newport Trust Co (1.19%), Boston Partners (1.16%) and Bank of New York Mellon Corp (0.90%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James J /Ky Obrien, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.

Which major investors are selling Humana stock?

HUM stock was sold by a variety of institutional investors in the last quarter, including GQG Partners LLC, Ceredex Value Advisors LLC, Maverick Capital Ltd., Marshall Wace North America L.P., Marshall Wace LLP, FMR LLC, Point72 Asset Management L.P. and Newport Trust Co. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Christopher H Hunter, Elizabeth D Bierbower, James J /Ky Obrien, Roy A Beveridge, Timothy Alan Wheatley and Timothy S Huval. View Insider Buying and Selling for Humana.

Which major investors are buying Humana stock?

HUM stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Boston Partners, First Trust Advisors LP, Panagora Asset Management Inc., Schroder Investment Management Group, Credit Suisse AG, PGGM Investments and Partner Fund Management L.P.. View Insider Buying and Selling for Humana.

How do I buy shares of Humana?

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Humana's stock price today?

One share of HUM stock can currently be purchased for approximately $375.85.


MarketBeat Community Rating for Humana (NYSE HUM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  775 (Vote Outperform)
Underperform Votes:  807 (Vote Underperform)
Total Votes:  1,582
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel